Elana Gotkine
MONDAY, Nov. 21, 2022 (HealthDay News) -- Vitamin D supplementation does not reduce the risk for asthma exacerbation in children overall,…
Presentation highlights a greater than 60% reduction in acute exacerbations and need for antibiotics for chronic sinusitis patients who used XHANCE in landmark ReOpen phase 3 clinical trial…
XHANCE is the first and only nasal medication ever shown in Phase 3 controlled trialsto reduce exacerbations for patients with chronic sinusitis Pre-planned analysis of pooled data from…
In a novel approach, researchers collaborated with patients to design and implement the trial.
A new approach to managing moderate-to-severe asthma has gained interest and attention and…
NEW YORK and LONDON, Jan. 26, 2022 (GLOBE NEWSWIRE) -- Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan…
The recommendations of an international expert panel to update the definition and severity classification of chronic obstructive pulmonary disease (COPD) exacerbations will be presented by…